Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE

Among patients with established cardiovascular disease, the ADAPTABLE trial found no significant differences in cardiovascular events and bleeding rates between 81 mg and 325 mg of aspirin (ASA) daily. In this secondary analysis from the ADAPTABLE trial, we studied the effectiveness and safety of AS...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2023-10, Vol.264, p.31-39
Hauptverfasser:	Gupta, Kamal, Mehta, Harsh, Kim, Hwasoon, Stebbins, Amanda, Wruck, Lisa M., Muñoz, Daniel, Effron, Mark B., Anderson, R. David, Pepine, Carl J., Jain, Sandeep K., Girotra, Saket, DeWalt, Darren A., Whittle, Jeff, Benziger, Catherine P., Farrehi, Peter, Zhou, Li, Knowlton, Kirk U., Polonsky, Tamar S., Bradley, Steven M., Harrington, Robert A., Rothman, Russell L., Jones, W. Schuyler, Hernandez, Adrian F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aspirin Aspirin - therapeutic use Atherosclerosis Bleeding Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - complications Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cerebral infarction Coronary vessels Creatinine Demographics Diabetes Disease prevention Dosage Effectiveness Electronic health records Hemorrhage - chemically induced Hemorrhage - complications Hemorrhage - epidemiology Hospitalization Humans Kidney diseases Kidneys Medicare Myocardial infarction Myocardial Infarction - etiology Patients Population Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Safety Secondary analysis Secondary Prevention Sensitivity analysis Statistical models Stroke Subgroups Vein & artery diseases Web portals
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!